MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049)

Migraine Clinical Trial

Official title:

A Phase IIa, Multicenter, Randomized, Placebo-controlled Clinical Trial to Study the Safety and Efficacy of MK0974 for Migraine Prophylaxis in Patients With Episodic Migraine

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00797667
• Other study ID #: 0974-049
• Secondary ID: 2008_591
• Status: Terminated
• Phase: Phase 2
• Start date: November 12, 2008
• Est. completion date: May 20, 2009

Study information

• Verified date: September 2018
• Source: Merck Sharp & Dohme Corp.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A study to assess the safety and efficacy of MK0974 for preventing migraines in patients with episodic migraine.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 660
• Est. completion date: May 20, 2009
• Est. primary completion date: May 20, 2009
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient is 18 years of age or older

• Patient has had a history of migraine with or without aura

• Patient is able to complete study questionnaire(s) and paper diary

Exclusion Criteria:

• Patient is pregnant or breast-feeding, or is a female expecting to conceive within the projected duration of the study

• Patient has basilar or hemiplegic migraine headache, hepatitis or psychiatric conditions

• Patient was older than 50 years of age at migraine onset

• History of gastric or small intestinal surgery or has a disease that causes malabsorption

• Patient has heart attack, unstable angina, coronary artery bypass surgery or other revascularization procedure, stroke, or transient ischemic attack 3 months before starting the study

• Currently participating or has participated in a study with an investigational compound or device within 30 days of starting the study

• Currently participating in a study with MK-0974 or MK-3207

Related Conditions & MeSH terms

• Migraine
• Migraine Disorders

Intervention

Drug:
• Telcagepant 140 mg

• Telcagepant 280 mg

• 140 mg telcagepant placebo

• 280 mg telcagepant placebo

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Merck Sharp & Dohme Corp.

References & Publications (1)

Ho TW, Connor KM, Zhang Y, Pearlman E, Koppenhaver J, Fan X, Lines C, Edvinsson L, Goadsby PJ, Michelson D. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology. 2014 Sep 9;83(11):958-66. doi: 10.1212/ — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Mean Monthly Headache Days	Participants entered information about the number of migraine headaches, symptoms, headache pain duration and severity, use of medication, and side effects into a diary each evening just before going to bed. This information was used to determine the mean monthly headache days; a headache day was defined as any day in which a qualified headache (>=30 minute duration or requiring acute treatment) started, ended, or recurred. Headache pain persisting for more than 1 calendar day after initial onset was considered an occurrence of multiple distinct headache days. Mean monthly rate was adjusted to 28 days.	Baseline and Week 12
Primary	Change From Baseline in Mean Monthly Migraine Days	Participants entered information about the number of migraine headaches, symptoms, headache pain duration and severity, use of medication, and side effects into a diary each evening just before going to bed. This information was used to determine the mean monthly migraine days; a migraine day was defined as any day in which a qualified headache( i.e., aura, photophobia, phonophobia, nausea, or vomiting) started, ended, or recurred. Migraine pain persisting for more than 1 calendar day after initial onset was considered an occurrence of multiple distinct migraine days. Mean monthly rate was adjusted to 28 days.	Baseline and Week 12
Primary	Percentage of Participants Who Experienced an Adverse Event	Participants were assessed throughout the study for adverse events and recorded adverse events in a daily dairy. An adverse event was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an adverse event.	up to 14 days after last dose of study drug (up to 12 weeks)
Primary	Percentage of Participants Who Had Study Drug Discontinued During the Study Due to an Adverse Event	Participants were assessed throughout the study for adverse events and recorded adverse events in a daily dairy. An adverse event was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an adverse event. The percentage of participants who discontinued study was summarized.	up to 12 weeks
Secondary	Percentage of Participants With at Least a 50% Reduction in Mean Monthly Headache Days	Participants entered information about the number of migraine headaches, symptoms, headache pain duration and severity, use of medication, and side effects into a diary each evening just before going to bed. This information was used to determine the mean monthly headache days; a headache day was defined as any day in which a qualified headache (>=30 minute duration or requiring acute treatment) started, ended, or recurred. Headache pain persisting for more than 1 calendar day after initial onset was considered an occurrence of multiple distinct headache days. Mean monthly rate was adjusted to 28 days. The percentage of participants who had at least a 50% reduction in mean monthly headache days during the 12 weeks treatment period was summarized	Week 12
Secondary	Change From Baseline in the Mean Monthly Migraine Attacks	Participants entered information about the number of migraine headaches, symptoms, headache pain duration and severity, use of medication, and side effects into a diary each evening just before going to bed. This information was used to determine the mean monthly migraine days; a migraine day was defined as any day in which a qualified headache was accompanied with associated symptoms.( i.e., aura, photophobia, phonophobia, nausea, or vomiting) started, ended, or recurred. A migraine attack was defined as any migraine headache that occurs within 2 consecutive calendar days. Pain persisting for more than 2 days after its initial onset was considered a new, distinct migraine attack. The number of migraine attacks that occurred per month was calculated. Mean monthly rate was adjusted to 28 days.	Baseline and Week 12
Secondary	Change From Baseline in the Mean Number of Days Per Month Requiring Rescue Medication	Participants completed a diary each evening just before going to bed. Information recorded included: date of assessment, administration of study medication, medication to treat breakthrough migraines and other headaches, associated symptoms, duration of headache pain, headache severity, and side effects. Participants use of medication to treat a breakthrough migraine/headache was considered rescue medication. The number of days per month requiring rescue medication was calculated.	Baseline and Week 12